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Highlights  
 3TC+DTG in simplification showed high efficacy.  
 The presence of M184V was significant in patients with shorter time of suppression.  
 We registered a rate of discontinuation of 10.7 per 100 PYFU.  
 The regimen led to an improvement in lipid profile. 
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Abstract 
Background. Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir 
could be an effective and tolerated option for simplification in HIV-1 positive patients. 
Materials and Methods. This was an observational study enrolling HIV-1-infected, virologically suppressed 
patients switching to lamivudine plus dolutegravir. We performed Kaplan-Meyer survival analysis to 
evaluate time to virological failure (VF, defined by a single HIV-RNA ≥1,000 copies/mL or by two 
consecutive HIV-RNA ≥ 50 copies/mL) and treatment discontinuation (TD, defined as the interruption of 
either 3TC or DTG), Cox-regression to assess predictors and linear mixed model for repeated measures to 
measure changes in immunological and metabolic parameters.  
Results. Five-hundred fifty-six patients were eligible for the analysis: median CD4+ count at baseline was 
668 cell/mm3, while median time of virological suppression was 88 months. Estimated probabilities of 
maintaining virological suppression at weeks 96 and 144 were 97.5% (SD ±0.8) and 96.5% (SD ±1.0). Years 
from HIV diagnosis were the only predictor of VF. In patients with time of virological suppression <88 
months, the rate of VF was higher in the presence of the M184V mutation. Estimated probabilities of 
remaining on 3TC+DTG at 96 and 144 weeks were 79.2% (SD ±1.9) and 75.2% (SD ±2.2). A significant 
increase in CD4 cell count (+44 cell/mm3, p=0.015), CD4/CD8 ratio (+0.10, p=0.002) and HDL cholesterol 
(+5.4 mg/dl, p=0.036) was found after 144 weeks; meanwhile total cholesterol (-9.1 mg/dl, p=0.007) and 
triglycerides (-2.7, p=0.009) significantly decreased. 
Conclusions. Our findings confirm the efficacy and tolerability of 3TC+DTG in virologically suppressed 
patients. 
Keywords: HIV; dual therapy; two-drug regimen; ART; simplification; lamivudine; dolutegravir.  
         
Introduction  
Combination antiretroviral therapy (cART) has dramatically decreased morbidity and mortality of the HIV-1-
infected population,1 and a prompt initiation of cART has demonstrated to be fundamental in reducing the 
burden of serious AIDS and non-AIDS related events, independently from CD4 cell counts.2 However, 
mathematical models forecast that in next few decades age-related comorbidities will become a substantial 
issue in HIV-infected individuals,3 especially due to an increased burden of cardiovascular diseases, diabetes 
and chronic kidney disease. Moreover, the indication to treat all HIV-1-infected patients regardless of CD4 
count4 raises the concern of the long-term treatment-related toxicities (especially those related to 
nucleoside reverse transcriptase inhibitors, NRTIs)5 and patients’ adherence.4,6 Finally, the increasing 
prevalence of HIV infection, of life expectancy of the infected population, and of projected lifetime 
healthcare costs also prompt the need for new treatment paradigms.7 
In selected patients, treatment simplification with two-drug regimens after achieving a stable virological 
suppression represents one of the recommended switch strategies in treatment guidelines.4,8 Among these 
strategies, in the recent past, lamivudine with boosted protease inhibitors (bPIs),9-12 and particularly with 
atazanavir,10,11 has shown the most robust data in terms of efficacy and safety. However, given the toxicity 
of bPIs, their impact on the individual’s metabolic profile9-12 and the potential for drug-drug interactions 
determined by the boosting agents,13 new switch strategies have emerged. Results from clinical trials and 
observational studies14-19 suggest that lamivudine plus dolutegravir could be a safe and effective option as 
well as a very well tolerated one but long-term data are still lacking in literature.  
We previously reported a single-center, long term analysis on 221 virologically suppressed switching to 
dolutegravir plus lamivudine patients with a median time of follow-up of 96 months.20 Goal of the present 
study was to confirm our preliminary findings in a multicenter cohort of adult HIV-1-infected patients, 
unselected for any criteria except for virological suppression at the time of switch. 
Materials and methods  
1 Study design. This was a retrospective, observational study in which we enrolled HIV-1-infected patients 
from nine Italian clinical centers. Criteria for eligibility were: patient’s informed consent to data collection, 
         
being at least 18 years-old, being on stable (i.e. at least 6 months) cART with viral suppression (HIV-RNA<50 
copies/mL) at the moment of switch to lamivudine plus dolutegravir (baseline) and HBsAg negative. All 
patients switched for clinical reason to lamivudine plus dolutegravir, following the principles expressed by 
Italian Guidelines on the management of HIV infection.21  
2 Ethic statement. The study was performed according to the principles of the Declaration of Helsinki and 
received the approval by each independent local Ethics Committee (study coordination site protocol 
number 5284/15). All patients signed informed consent.  
3 Statistical analysis.  The primary study objective was to evaluate the time to virological failure (VF, 
defined by a single HIV-1 RNA ≥1,000 copies/mL or by two consecutive HIV-1 RNA ≥ 50 copies/mL) and the 
time to treatment discontinuation (TD, defined as the interruption of either 3TC or DTG) for any cause. 
Survival analysis was employed to determine the time to TD and VF and the respective predictors were 
analyzed by Cox regression. Changes from baseline in immunological parameters (absolute and percentage 
CD4+ T-cell counts, CD4/CD8 ratio), estimated glomerular filtration rate (eGFR) (by the MDRD study 
equation), and blood lipids (total/HDL cholesterol ratio, triglycerides) at weeks 48, 96 and 144 were 
evaluated via linear mixed models for repeated measures. Linear regression was performed to explore 
variables associated to significant changes in laboratory parameters.  
Results  
1 Study population  
Five-hundred fifty-six patients were eligible for the analysis: 391 (70.3%) were males, 125 (22.5%) were 
HCV-coinfected while 81 (14.6%) had a previous AIDS-defining event. Median age at baseline was 51.7 
years (IQR 45.3-57.4), median time from HIV diagnosis was 15.4 years (IQR 8.5-22.1), with a median time of 
cART exposure of 11.5 years (IQR 6.1-18.3).  
Two hundred twenty-six patients (40.6%) had experienced at least one virological failure; among them, 158 
(69.9%) had more than 1 virological failure and median number of previous VF was 2 (IQR 1-4). Almost all of 
         
them (223/226, 98.7%) experienced at least one VF while in therapy with NRTIs and, in particular, 93 
(41.1%) with TDF and 172 (76.1%) with 3TC. One hundred seventy-two patients (76.1%) had a VF while on a 
NNRTI, while 163 (72.1%) while in therapy with a PI (21 of which while on DRV). Finally, 9 (4.0%) 
experienced a VF while on a INI-based regimen (7 with RGV and 2 with EVG). 
Median CD4+ count at baseline was 668 cell/mm3 (IQR 495-890), while median time of virological 
suppression was 88.0 months (IQR 44.1-122.7). The M184V resistance mutation was present in 45 (8.1%) 
patients, of which 28 (10.4%) among the 270 patients with a time of virological suppression over 88 months 
and 17 (6.1%) among the 277 patients with a time of virological suppression below 88 months. Full 
patients’ characteristics are shown in Table 1. 
At the moment of switch, 224 (40.3%) patients were already on a dual ART (171 of whom with lamivudine 
plus bPI), while 307 (55.7%) were on a standard triple regimen with 2NRTIs and a third drug (141 with a 
NNRTI, 89 with an InSTI and 77 with a boosted PI).  Fifty-two patients (9.4%) were on a regimen containing 
DTG before switching to the study regimen. Reasons for switching were mainly represented by 
simplification (27.9%), dyslipidemia (16.5%), gastro-intestinal toxicity (7.9%) or other toxicities (13.9%). Of 
note, the M184V resistance mutation to lamivudine was present in 45 (8.1%) patients in at least one 
previous genotypic resistance test.  
2 Virological efficacy  
The median follow-up time was 22.1 months (11.4-33.5). Twelve VF were detected over 1020.1 person-
years of follow-up (PYFU) with an overall incidence of 1.2 VF per 100 PYFU. Seven of these patients 
discontinued 3TC+DTG: 4 were switched to a dolutegravir-based triple-regimen (2 with ABC/3TC and 2 with 
FTC/TDF), 2 were switched to FTC/TDF plus boosted DRV and 1 patient started ATV+DTG. The remaining 
five patients maintained study regimen. All of the patients experiencing VF re-achieved virologic control 
subsequently, while none of them developed resistance mutation after failure. The Kaplan-Meier curve for 
time to VF is shown in figure 1. The estimated probability of maintaining virological suppression at weeks 
48, 96 and 144 were 98.7% (SD ±0.5), 97.5% (SD ±0.8) and 96.5% (SD ±1.0), respectively. We found that 
         
years from HIV diagnosis were the only predictor of VF (aHR 1.1, 95% CI 1.1 – 1.2, p=0.030) after adjusting 
for the presence of the M184V resistance mutation, time of virological suppression, nadir and baseline 
CD4+ cells count, HIV risk factor and switching from a PI-based regimen.  
The presence of the M184V resistance mutation alone was not a predictor of VF; however, stratifying by 
time of virological suppression, we observed that, in patients with time of virological suppression < 88 
months, the rate of VF was higher in the presence of the M184V mutation (6.7 per 100 PYFU vs 1.0 per 100 
PYFU, Log-Rank p=0.014). Conversely, VF rates were not different in patients with time of virological 
suppression longer than 96 months, independently from M184V mutation (Log Rank p=0.308) (Table 2 and 
Figure 1).  
3 Treatment discontinuations 
One hundred and ten treatment discontinuations occurred over 1025.6 PYFU (10.7 per 100 PYFU), with an 
estimated probability of remaining on lamivudine plus dolutegravir of 86.1% (SD ±1.5), 79.2% (SD ±1.9) and 
75.2% (SD ±2.2) at weeks 48, 96 and 144, respectively. Median time to TD was 29.6 weeks (IQR 12.4-59.6).  
Reasons for TD were represented by: virological failure (7 of 556, 1.3%), toxicity (43, 7.7%, of which 18 for 
neuropsychological events, 9 for gastrointestinal and hepatic toxicity, 6 for renal toxicity, 1 following a 
hypersensitivity reaction and 9 for other toxicities), further simplification to a single tablet regimen (7 
cases, 1.3%),  drug-drug interactions (2 cases, 0.4%), death (6, 1.1%) and other/unknown causes (41, 7.4%). 
Among the 18 discontinuations caused by neuropsychological events, 8 were due to insomnia, 5 to 
headache, 3 to mood disorders and one was due to the sudden onset of nightmares. Of note, all of the 
adverse events leading to TD were of mild or moderate severity. Switching to study regimen for drug-drug 
interaction (vs switching for simplification, aHR 2.4, 95% CI 1.4-4.4, p=0.003) was a predictor of 
discontinuation, after adjusting for clinical center, years of HIV and HIV risk factor. 
Evaluating discontinuations due to overall toxicity, the estimated probabilities of maintaining study 
regimen were 93.8% (SD ±1.1) at week 48, 91.4% (SD ±1.3) at week 96 and 90.4% (SD ±1.5). Switching to 
study regimen for toxicity (vs switching for simplification, aHR 3.1, 95% CI 1.4-6.9, p=0.006) was the only 
         
predictor of TD at a multivariate analysis, after adjusting for clinical center, HIV risk factor and a history of a 
previous dual regimen.  
A specific survival analysis evaluating TD due only to neuropsychological events show that the estimated 
probabilities of remaining free from TD were 97.2% (SD ±0.7) at week 48 and 96.1% (SD ±0.9) at weeks 96 
and 144 (Figure 2). At a multivariate regression analysis, we found that HCV-coinfection (aHR 6.2, 95% CI 
2.3-16.4, p<0.001) was a predictor of discontinuations due to CNS toxicity after adjusting for age, sex and 
previous cART. 
4 Immunological assessment  
Absolute CD4+ T-cell count significantly increased in patients with available data at 96 weeks of follow-up 
(median change +60 cell/mm3, p<0.001) as well as in patients with available data at 144 weeks (median 
change +44 cell/mm3, p=0.015). At a multivariate analysis both age (per 10 years more, -31.7, 95% CI -54.7 
; -8.5, p=0.007) and baseline CD4+ T-cell count (per 10 cell/mm3 more, -2.4, 95% CI -3.3 ; -1.5, p<0.001) 
negatively predicted an improvement in CD4+ T-cell count at 96 weeks after adjusting for peak HIV-RNA 
viral load. Baseline CD4+ T-cell count was the only negative predictor (per 10 cell/mm3 more, -2.7, 95% CI -
4.0 ; -1.3, p<0.001) of CD4+ improvement at 144 weeks. 
An increase in CD4/CD8 ratio was evidenced overall considering patients with available data at 96 weeks of 
follow-up with a significant difference in median change (+0.06, p=0.001). The trend was confirmed in the 
group of 46 patients with data at 144 weeks of follow-up, with a median change in CD4/CD8 ratio of +0.10 
(p=0.002) (Figure 2a). Evaluating the proportion of patients achieving a CD4/CD8 ratio ≥1, this was 
significantly higher both at 96 and 144 weeks of follow-up compared with baseline values; in particular, 
CD4/CD8 ratio was ≥1 in 39/125 patients (31.2%) at baseline and in 51/125 (40.8%) at 96 weeks (p<0.001). 
Among patients with 144 weeks of follow-up, 13/53 (24.5%) had a CD4/CD8 ratio ≥1 at baseline while the 
proportion was significantly higher at 144 weeks (20/53, 37.7%, p<0.001). At a multivariate analysis, time of 
virological suppression was the only predictor of change in CD4/CD8 ratio both at 96 and 144 weeks.  
 
         
5 Metabolic profile 
A significant reduction in total cholesterol was found in patients with 144 weeks of follow-up (median 
change -9.1 mg/dl, p=0.007) (Figure 2b) while it was not observed among patients with only 96 weeks of 
follow-up (p=0.075). An increase in total cholesterol at 144 weeks was observed in patients switching from 
a FTC/tenofovir based regimen (+21.7 mg/dl, 95% CI 2.0-41.3, p=0.031) while a higher value of total 
cholesterol at baseline was associated with a more pronounced improvement at 144 weeks (-0.4 mg/dl, 
95% CI -0.5 ; -0.2, p<0.001), after adjusting for triglycerides’ baseline value. In our cohort we also registered 
a significant improvement in HDL cholesterol both in patients with 144 weeks (+5.4 mg/dl, p=0.036) (Figure 
2c). A greater improvement was predicted at both 96 (per 1 mg/dL more, -0.2, 95% CI -0.3 ; -0.1, p<0.001) 
and 144 weeks (per 1 mg/dL more, -0.3, 95% CI -0.4 ; -0.1, p<0.001) by baseline HDL values, after adjusting 
for LDL cholesterol values at baseline and time of virological suppression. 
We observed a significant decrease in triglycerides’ levels in patients with data at 96 (median change -10.8, 
p<0.001) and 144 weeks (-2.7, p=0.009) (Figure 2d). Baseline values were predictive of a more pronounced 
improvement at both 96 (per 1 mg/dl more, -0.5, 95% CI -0.6 ; -0.3, p<0.001) and 144 weeks (per 1 mg/dl 
more, -0.8, 95% CI -0.9 ; -0.6, p<0.001), after adjusting for HIV risk factors and total cholesterol baseline 
levels.   
Focusing on patients switching from 3TC + PI, we observed a more pronounced improvement in both total 
cholesterol levels and triglycerides at 144 weeks: in particular, we found a median decrease of total 
cholesterol of -19.0 mg/dL (p=0.036) and of triglycerides of -52.1 mg/dL (p=0.006).  
As to the renal function, we observed a significant decrease in eGFR in patients with data at 96 weeks 
(median change -9.6 ml/min, p<0.001) and in those with data at 144 weeks (-5.2 ml/min, p<0.001). Baseline 
eGFR was related to a less marked decrease at both 96 (per 1 ml/min more, -0.3, 95% CI -0.4 ; -0.1, 
p<0.001) and 144 weeks (per 1 ml/min more, -0.3, 95% CI -0.5 ; -0.1, p<0.001); also, female sex (vs male 
sex, -7.4, 95% CI -13.1; -1.6, p=0.013) and coming from PI-based dual regimen (-5.4, 95% CI -10.7 ; -0.1, 
p=0.046) resulted protective at 96 weeks.  
         
Discussion 
Results from this multicenter study, conducted in a real-life setting, strengthen our previous monocentric 
work20 with a large sample size (556 vs 221) and a longer follow-up time (1020.1 vs 419.7 PYFU) and 
confirm findings on the efficacy of a dual regimen of lamivudine and dolutegravir in virologically suppressed 
HIV1-infected patients.14,16,17,22   
In particular, we observed a low rate of virological failures (an overall incidence of 1.2 VF per 100 PYFU) and 
an estimated probability of maintaining virological suppression of 96.5% at 144 weeks. It is to be noted, 
moreover, that none of the 12 patients experiencing virological failure developed resistance mutations to 
DTG or 3TC, a finding in line with what described by Joly et al,16 further confirming the high genetic barrier 
of dolutegravir,23 a characteristic that makes this drug suitable for a two-drug regimen. Regarding 
virological efficacy of this regimen, it is worth noting that data on patients’ compliance to the regimen, a 
possible factor relating to HIV-RNA increases, were not collected in our study. Further insights are hence 
needed to assess the topic. Furthermore, the virological dynamics may be more thoroughly evaluated with 
studies aimed at evaluating the residual viremia and especially the viral reservoirs, first of all the HIV-DNA 
dosage, as already investigated in other two-drug regimens.24 Our study also allows to frame the target of 
patients for whom this switch strategy may results more advantageous; in particular our data confirm that, 
even with a longer follow-up, the lone presence of the M184V resistance mutation is not a predictor of 
virological failure for this 3TC-containing dual regimen, probably because of the reduced replicative fitness 
caused to the virus by this mutation.25-27 However, as previously reported by Gagliardini et al,28 the M184V 
mutation appears to be associated with virological failure in patients with a reduced time of virological 
suppression at baseline. These results must bring to the attention of the clinician the need to collect a 
precise clinical and virological history of the patient before implementing a therapeutic simplification 
towards a two-drug regimen.   
In our population we observed 110 discontinuations (19.8% of the total population), the majority of which 
(91) during the first 60 weeks of follow-up. Overall toxicity was the main reason for discontinuing study 
         
regimen (43 cases, 7.7% of our cohort) and, among those, the majority (18) were due to neuropsychological 
events. The rate of overall discontinuations appears in line with other studies on dolutegravir,29 while it 
appears sensibly higher when compared to other cohorts.22 This difference might be related to the longer 
follow-up time of our study, a unique finding not present in other works form the literature, that further 
reinforces our results. Focusing on CNS toxicity, a feature already described in other studies on DTG29,30 we 
reported that eighteen patients, the majority of which reported sleep disorders or a newly onset headache 
as the main problems, discontinued study regimen following these adverse events. The rate of 
discontinuations due to neuropsychological events appears higher compared to the cohort of Maggiolo et 
al,22 in which just 2/218 patients discontinued 3TC+DTG, one for headache and one for vertigo. Interesting 
is the correlation between treatment discontinuations due to neuropsychiatric disorders and co-infection 
with hepatitis C virus, which has previously been associated with multiple neuropsychiatric disorders, in 
particular asthenia, depression and cognitive dysfunction.31  Factors predisposing to the onset of 
neuropsychiatric disorders in patients on therapy in DTG have already been investigated31,32 and could be a 
starting point for further research and analysis within our cohort. The limitation of our study is that of not 
having collected any adverse events occurred during therapy not causing discontinuation of the regimen. 
Regarding the improvement in immunological parameters, particularly interesting is the increase of the 
CD4/CD8 ratio, providing further evidence of the efficacy of this regimen also on the immunological level, 
with the limitation of the lack of a control group. As to the apparent worsening of renal function, the 
decrease in the glomerular filtration rate found in our population, predominantly in the first 48 weeks of 
follow-up, could probably be attributed to an intrinsic characteristic of dolutegravir. In fact, it inhibits the 
organic cation transporter 2 (OCT2), reducing the excretion at the tubular level of creatinine.33 In 
agreement with previous results and other studies in the literature,22,34 the lipid profile of the patients in 
the study finds benefit from the simplification to the dual regimen with lamivudine and dolutegravir. In 
fact, both total cholesterol and triglyceride levels decrease during follow-up, especially in those patients 
who have a higher starting value at the time of the switch. It is to be noted that almost a third of the 
patients switched from another dual regimen with 3TC + bPI; in those patients the improvement in lipid 
profile was more pronounced.  
         
In our experience, the two-drug regimen with lamivudine and dolutegravir in the context of therapeutic 
optimization with suppressed viremia has shown excellent virological efficacy and good tolerability. 
Alongside these, the low presence of drug interactions and independence from food intake make this 
regime suitable for a very large population of HIV-infected patients, given the current trend of an aging 
population and the increase in incidence of comorbidity and polypharmacy. The strengths of our study are 
the sample size of our cohort, the real life setting and the duration of the follow-up; the limits are dictated, 
instead, by the retrospective nature of the study, the lack of a control arm and the lack of recording of 
some data, in particular adverse events that did not lead to suspension of the regime and further virological 
investigations (i.e. HIV-DNA).  
Conclusions.  
Lamivudine plus dolutegravir was effective in maintaining viral suppression in a large proportion of patients 
from a multicenter cohort of long term treated, HIV-1-positive patients with undetectable HIV-RNA at the 
time of switch. Even though further studies will be needed to assess the efficacy and safety of the regimen, 
in our opinion the patients’ clinical history, including any co-infections with hepatitis viruses, and the 
patient's viro-immunological status at the time of therapeutic optimization should be carefully analyzed by 
the clinician when considering the switch to a dual therapy.  
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Table 1. Patients’ characteristics at baseline (N 556)  
Variables   
Age (years), Median (IQR)  51.7 (45.3-57.4) 
Female, n (%) 165 (29.7) 
Risk factor for HIV infection, n (%): 
- Heterosexual  
- MSM 
- IDU 
- Others 
 
225 (40.5) 
145 (26.1) 
100 (18.0) 
86 (15.5) 
Anti-HCV antibodies positive, n (%) 125 (23.0) 
Time from HIV diagnosis (years), Median (IQR)  15.4 (8.5-22.1) 
CDC stage C, n (%) 81/325 (24.9) 
Time on antiretroviral therapy (years), Median (IQR)  11.5 (6.1-18.3) 
Nadir of CD4+ (cell/µL), Median (IQR) 230 (98-328) 
Zenith HIV-RNA (log10 copies/mL), Median (IQR) 4.93 (4.39-5.42) 
Patients with a zenith HIV-RNA > 500000 copies/mL,      
n (%) 
73 (14.1) 
Previous virological failure, n (%) 226 (40.7) 
CD4+ count (cell/µL), Median (IQR) 668 (495-890) 
CD4/CD8 ratio, Median (IQR) 0.85 (0.61-1.13) 
Time of virological suppression (months), Median (IQR)  88.0 (44.1-122.7) 
M184V resistance mutation, n (%) 
- Present  
- Absent  
- Unknown  
 
45 (8.1) 
406 (73.0) 
105 (18.9) 
Previous HAART regimen, n (%): 
- 2NRTIs+NNRTI  
- 2NRTIs+PI or b/PI 
- 2NRTIs+INI 
- Dual therapy 
- Other 
 
141 (25.6) 
77 (14.0) 
89 (16.2) 
224 (40.7) 
20 (3.6) 
FTC/TDF in previous regimen, n (%) 231 (41.9) 
DTG in previous regimen, n (%) 52 (9.4) 
3TC + PI in previous regime, n (%) 171 (31.0) 
Reasons for switch, n (%): 
- Simplification  
- Dyslipidemia  
 
155 (27.9) 
92 (16.5) 
         
- Gastrointestinal or liver toxicity  
- Renal toxicity  
- Osteoporosis 
- Neurological toxicity  
- Other toxicities  
- Drug-drug interactions 
- Cardiovascular risk  
- Other/Unknown reasons 
44 (7.9) 
30 (5.4) 
27 (4.9) 
7 (1.3) 
13 (2.3) 
36 (6.5) 
16 (2.9) 
136 (24.5) 
 
 
         
Table 2. Patients (Pt) that incurred in virological failure (VF) during the follow-up.  
Pt  Sex and 
Age 
Time to 
VF 
(months) 
Type 
of VF* 
HIV-RNA 
at VF 
(cp/mL) 
Subsequent 
therapy 
Presence of 
M184V/I 
mutation 
Comments  
Pt 1 Female, 
50 yrs 
8.5 1 74.570 FTC/TDF + DRV/rit No She reported lack of adherence  
Pt 2 Male, 
40 yrs 
29.0 1 4.057 3TC + DTG No He reported lack of adherence. The study regimen was not 
interrupted and following HIV-RNA determination was < 50 
cp/mL. 
Pt 3 Female, 
43 yrs 
11.9 1 775.000 FTC/TAF/EVG/cob No She reported lack of adherence. Following HIV-RNA 
determination were > 50 cp/mL 
Pt 4 Male, 
45 yrs 
4.7 1 1.808 3TC + DTG No The study regimen was not interrupted and following HIV-RNA 
determination was < 50 cp/mL.  
Pt 5 Male, 
55 yrs 
19.0 2 112; 64 3TC/ABC/DTG No He achieved virological suppression after 4 months.  
Pt 6 Male, 
49 yrs 
18.6 2 69; 108 ATV + DTG Yes He achieved virological suppression at the following 
determination of HIV-RNA. 
Pt 7 Male, 
31 yrs 
4.6 2 58.830 FTC/TDF + ATV/rit  No He reported lack of adherence. Following HIV-RNA 
determination < 50 cp/mL.  
Pt 8 Female, 
51 yrs 
17.1 2 79; 59 3TC/ABC/DTG No She achieved virological suppression at the following 
determination of HIV-RNA. 
Pt 9 Female, 
48 yrs 
16.6 2 58; 53 3TC + DRV/cob  No Confirmed blips in two consecutive viremia; not known lack of 
adherence. 
Pt 
10 
Female, 
50 yrs 
26.6 1 15.893 Unknown No Lack of adherence. She re-started the same treatment with 
undetectability after 2 months. 
         
Pt 
11 
Male, 
28 yrs 
9.5 1 1.232 TDF/FTC + DTG Yes He reported lack of adherence with treatment interruption, 
switched in triple treatment considering the presence of 184V in 
a previous GRT in Paediatric; vertically infected.  
Pt 
12 
Male, 
64 yrs  
7.7 2 75; 65 TDF/FTC + DTG  No Confirmed blips in two consecutive viremia but during flu 
vaccination; good adherence but GRT not performed at failure. 
*1= one single HIV-RNA determination ≥ 1000 cp/mL; 2= two consecutive HIV-RNA determination ≥ 50 cp/mL. 
         
Figure 1. Kaplan-Meyer survival curves for the probability of maintaining virological suppression: 
(a) overall; (b) stratified for the presence of M184V resistance mutation; (c) stratified for the 
presence of M184V mutation in patient with a virological suppression ≥ 88 months; (d) stratified 
for the presence of M184V mutation in patient with a virological suppression < 88 months.  
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Figure 2. Variation in median CD4/CD8 ratio (a), median total cholesterol (b), median HDL 
cholesterol (c) and median tryglicerides during the follow-up.  
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